Stromal expression of β-arrestin-1 predicts clinical outcome and tamoxifen response in breast cancer.
AffiliationDepartment of Laboratory Medicine, Center for Molecular Pathology, Lund University, Malmö University Hospital, Malmö, Sweden.
MetadataShow full item record
AbstractThe G-protein coupled receptor associated protein β-arrestin-1 is crucial for the regulation of numerous biological processes involved in cancer progression, such as intracellular signaling and cell motility. The encoding gene ARRB1 is harbored in the same chromosomal region as the CCND1 gene (11q13). Amplification of CCND1, frequently encountered in breast cancer, often involves coamplification of additional oncogenes, as well as deletion of distal 11q genes. We investigated the clinical relevance of β-arrestin-1 in breast cancer and elucidated a potential link between β-arrestin-1 expression and CCND1 amplification. β-Arrestin-1 protein expression was evaluated in two breast cancer patient cohorts, comprising 179 patients (cohort I) and 500 patients randomized to either tamoxifen or no adjuvant treatment (cohort II). Additionally, migration after β-arrestin-1 overexpression or silencing was monitored in two breast cancer cell lines. Overexpression of β-arrestin-1 reduced the migratory propensity of both cell lines, whereas silencing increased migration. In cohort I, high expression of stromal β-arrestin-1 was linked to reduced patient survival, whereas in cohort II both high and absent stromal expression predicted a poor clinical outcome. Patients exhibiting low or moderate levels of stromal β-arrestin-1 did not benefit from tamoxifen, in contrast to patients exhibiting absent or high expression. Furthermore, CCND1 amplification was inversely correlated with tumor cell expression of β-arrestin-1, indicating ARRB1 gene deletion in CCND1-amplified breast cancers.
CitationStromal expression of β-arrestin-1 predicts clinical outcome and tamoxifen response in breast cancer. 2011, 13 (3):340-51 J Mol Diagn
JournalJournal of Molecular Diagnostics
- Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer.
- Authors: Lundgren K, Holm K, Nordenskjöld B, Borg A, Landberg G
- Issue date: 2008
- Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer.
- Authors: Bostner J, Ahnström Waltersson M, Fornander T, Skoog L, Nordenskjöld B, Stål O
- Issue date: 2007 Oct 25
- RSF1 and not cyclin D1 gene amplification may predict lack of benefit from adjuvant tamoxifen in high-risk pre-menopausal women in the MA.12 randomized clinical trial.
- Authors: Keilty D, Buchanan M, Ntapolias K, Aleynikova O, Tu D, Li X, Shepherd L, Bramwell V, Basik M
- Issue date: 2013
- Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification.
- Authors: Jirström K, Stendahl M, Rydén L, Kronblad A, Bendahl PO, Stål O, Landberg G
- Issue date: 2005 Sep 1
- Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers.
- Authors: Brown LA, Johnson K, Leung S, Bismar TA, Benítez J, Foulkes WD, Huntsman DG
- Issue date: 2010 Jun